Xiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Xiel Limited is a specialist in nuclear medicine and radiotherapy, serving the UK and Irish markets. The company primarily provides nuclear medicine and radiotherapy capital and services to hospitals, universities, research institutes and private companies, tailoring their offerings to meet specific customer needs.
MIS Healthcare is a UK-based exclusive distributor for world-leading medical manufacturers offering state-of-the-art products, including high-end medical imaging diagnostic equipment, PACS/RIS, medical consumables and diagnostic instruments. The company aims to become a leading specialist in the diagnostic imaging, radiology and oncology markets.
Oaklins Evelyn Partners, one of Oaklins’ member firms in the UK, served as the corporate finance advisor to the shareholders of Xiel Limited.
Talk to the deal team
Alfred Wigmore
Oaklins Evelyn Partners
Related deals
Den Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Learn moreMicrofinanciera Fundeser has been sold to Grupo Financiero Atlántida
Incofin has successfully exited its investment in Microfinanciera Fundeser in Nicaragua through two of its funds: Rural Impulse Fund II (RIF II) and agRIF. It has sold 100% of its stake in Microfinanciera Fundeser to Grupo Financiero Atlántida through its subsidiary, Inversiones Tres Lagos.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn more